2024
rBMA: A robust Bayesian Model Averaging Method for phase II basket trials based on informative mixture priors
Wang X, Wei W. rBMA: A robust Bayesian Model Averaging Method for phase II basket trials based on informative mixture priors. Contemporary Clinical Trials 2024, 140: 107505. PMID: 38521384, DOI: 10.1016/j.cct.2024.107505.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBayes TheoremClinical Trials, Phase II as TopicComputer SimulationHumansModels, StatisticalNeoplasmsResearch DesignConceptsPhase II basket trialRobust Bayesian modelBasket trial designBiomarker-defined subgroupsMixture priorsBinary endpointsModel averaging methodPosterior distributionBayesian modelBasket trialsSimulation studyEra of targeted therapyDevelopment of targeted agentsPriorsAverage methodGenomic alterationsPatient populationNovel treatmentAntitumor activityPosterior weightsEarly phase oncology trialsStatistical powerOncology trialsTrial designTrials
2022
Bayesian local exchangeability design for phase II basket trials
Liu Y, Kane M, Esserman D, Blaha O, Zelterman D, Wei W. Bayesian local exchangeability design for phase II basket trials. Statistics In Medicine 2022, 41: 4367-4384. PMID: 35777367, PMCID: PMC10279458, DOI: 10.1002/sim.9514.Peer-Reviewed Original Research
2021
Unified exact design with early stopping rules for single arm clinical trials with multiple endpoints
Wei W, Esserman D, Kane M, Zelterman D. Unified exact design with early stopping rules for single arm clinical trials with multiple endpoints. Statistical Methods In Medical Research 2021, 30: 1575-1588. PMID: 34159859, PMCID: PMC8959087, DOI: 10.1177/09622802211013062.Peer-Reviewed Original Research